MX2022013945A - Nuevas proteinas de union a repeticiones de anquirina y sus usos. - Google Patents

Nuevas proteinas de union a repeticiones de anquirina y sus usos.

Info

Publication number
MX2022013945A
MX2022013945A MX2022013945A MX2022013945A MX2022013945A MX 2022013945 A MX2022013945 A MX 2022013945A MX 2022013945 A MX2022013945 A MX 2022013945A MX 2022013945 A MX2022013945 A MX 2022013945A MX 2022013945 A MX2022013945 A MX 2022013945A
Authority
MX
Mexico
Prior art keywords
proteins
ankyrin repeat
binding proteins
nucleic acids
repeat binding
Prior art date
Application number
MX2022013945A
Other languages
English (en)
Inventor
Marcel Walser
Patrick Amstutz
Valerie Perrine Calabro
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of MX2022013945A publication Critical patent/MX2022013945A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a proteínas de unión recombinantes que comprenden uno o más dominios de repetición de anquirina diseñados con especificidad de unión para proteínas de espiga de coronavirus, ácidos nucleicos que codifican dichas proteínas, composiciones farmacéuticas que comprenden dichas proteínas o ácidos nucleicos, y el uso de dichas proteínas, ácidos nucleicos o composiciones farmacéuticas en el tratamiento de enfermedades por coronavirus, particularmente enfermedades causadas por el SARS-CoV-2.
MX2022013945A 2020-05-06 2021-05-06 Nuevas proteinas de union a repeticiones de anquirina y sus usos. MX2022013945A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063021024P 2020-05-06 2020-05-06
US202063020882P 2020-05-06 2020-05-06
US202063057477P 2020-07-28 2020-07-28
US202063069174P 2020-08-24 2020-08-24
US202163145192P 2021-02-03 2021-02-03
PCT/IB2021/000320 WO2021224686A1 (en) 2020-05-06 2021-05-06 Novel ankyrin repeat binding proteins and their uses

Publications (1)

Publication Number Publication Date
MX2022013945A true MX2022013945A (es) 2023-02-14

Family

ID=78412258

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013945A MX2022013945A (es) 2020-05-06 2021-05-06 Nuevas proteinas de union a repeticiones de anquirina y sus usos.

Country Status (16)

Country Link
US (2) US11466062B2 (es)
EP (1) EP4146691A1 (es)
JP (1) JP2023525518A (es)
KR (1) KR20230006558A (es)
CN (1) CN115916815A (es)
AU (1) AU2021267411A1 (es)
BR (1) BR112022022456A2 (es)
CA (1) CA3176845A1 (es)
CL (1) CL2022003044A1 (es)
CO (1) CO2022016595A2 (es)
CR (1) CR20220618A (es)
IL (1) IL297940A (es)
MX (1) MX2022013945A (es)
PE (1) PE20231074A1 (es)
TW (1) TW202208404A (es)
WO (1) WO2021224686A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114929730A (zh) * 2019-12-11 2022-08-19 分子合作伙伴股份公司 重组肽-mhc复合物结合蛋白及其生成和用途
MX2022013945A (es) * 2020-05-06 2023-02-14 Molecular Partners Ag Nuevas proteinas de union a repeticiones de anquirina y sus usos.
JP2023528204A (ja) 2020-05-14 2023-07-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
US11981710B2 (en) 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
EP3957649A1 (en) * 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
TWI796597B (zh) * 2020-09-21 2023-03-21 長庚大學 使用紫蘇之經水萃取的產物來對抗冠狀病毒感染的方法
JP2023550094A (ja) * 2020-11-12 2023-11-30 ティースキャン セラピューティクス インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２免疫優性ペプチドの構築物及びその使用
WO2022150636A1 (en) * 2021-01-07 2022-07-14 The Board Of Regents Of The University Of Texas System Engineered stable ace2 protein variants as antiviral nebulized therapeutics
JP2024509904A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ
WO2023056118A1 (en) * 2021-10-02 2023-04-06 Massachusetts Institute Of Technology Engineered alum-binding sars-cov-2 immunogens
WO2023154841A2 (en) * 2022-02-11 2023-08-17 The Texas A&M University System Sars-cov-2 neutralizing synthetic proteins
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
CN101875919A (zh) 2004-11-12 2010-11-03 拜耳先灵医药股份有限公司 重组新城疫病毒
RU2412249C2 (ru) 2005-07-08 2011-02-20 Юниверсити Оф Цюрих Фаговый дисплей с применением котрансляционной транслокации слитых полипептидов
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
EP2358746B1 (en) 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
EP2643349B1 (en) 2010-11-26 2019-09-04 Molecular Partners AG Designed repeat proteins binding to serum albumin
KR20140039203A (ko) 2011-04-29 2014-04-01 얀센 바이오테크 인코포레이티드 Il4/il13 결합 반복 단백질 및 용도
WO2014001442A1 (en) * 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
JP2015532306A (ja) 2012-10-15 2015-11-09 チューリッヒ大学 癌治療のための二重特異性ｈｅｒ２リガンド
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
US9458211B1 (en) 2015-04-02 2016-10-04 Molecular Partners Ag Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
AR109680A1 (es) 2016-09-22 2019-01-09 Molecular Partners Ag Proteínas recombinantes y sus usos
EP3980452A1 (en) 2019-06-04 2022-04-13 Molecular Partners AG Recombinant 4-1bb binding proteins and their use
CA3138805A1 (en) 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
AU2020289080A1 (en) 2019-06-04 2021-12-23 Molecular Partners Ag Multispecific proteins
AU2020286600A1 (en) 2019-06-04 2021-12-23 Molecular Partners Ag Recombinant FAP binding proteins and their use
WO2021116470A2 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
CN114929730A (zh) 2019-12-11 2022-08-19 分子合作伙伴股份公司 重组肽-mhc复合物结合蛋白及其生成和用途
MX2022013945A (es) * 2020-05-06 2023-02-14 Molecular Partners Ag Nuevas proteinas de union a repeticiones de anquirina y sus usos.

Also Published As

Publication number Publication date
EP4146691A1 (en) 2023-03-15
US20210347835A1 (en) 2021-11-11
TW202208404A (zh) 2022-03-01
IL297940A (en) 2023-01-01
CL2022003044A1 (es) 2023-06-02
CR20220618A (es) 2023-01-19
JP2023525518A (ja) 2023-06-16
CA3176845A1 (en) 2021-11-11
US20220235103A1 (en) 2022-07-28
US11466062B2 (en) 2022-10-11
KR20230006558A (ko) 2023-01-10
CO2022016595A2 (es) 2022-12-09
AU2021267411A1 (en) 2022-12-08
PE20231074A1 (es) 2023-07-17
BR112022022456A2 (pt) 2023-01-10
WO2021224686A1 (en) 2021-11-11
CN115916815A (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
MX2022013945A (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos.
MX2022007122A (es) Dominios de repetición de anquirina diseñados con residuos de superficie alterados.
PH12019500596A1 (en) Recombinant binding proteins and their use
SA517390092B1 (ar) مجالات تكرار أنكيرين مصمَّمة ذات نوعية ربط تجاه ألبومين مصل
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
TN2012000372A1 (en) Fibronectin based scaffold domain proteins that bind il-23
MX2022014326A (es) Proteinas multiespecificas.
PH12022550693A1 (en) Multi-specific binding proteins for cancer treatment
BRPI1013877A2 (pt) Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
MX2022011394A (es) Composiciones y metodos para la induccion de una respuesta inmune.
BR112018014288A2 (pt) métodos e composições para o tratamento de doença neurológica
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
PH12022551332A1 (en) Compositions and methods for simultaneously modulating expression of genes
ZA202403355B (en) Single domain antibodies binding to tetanus neurotoxin
WO2022150654A3 (en) Antigen-binding polypeptides specific for coronaviruses and uses thereof
MX2021008126A (es) Vacuna de arnm.
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
WO2023031306A3 (en) New coronavirus vaccine and method for designing and obtaining a virus vaccine
WO2025163083A8 (en) Recombinant dll3 binding proteins and their use
MX2025010057A (es) Moléculas multivalentes de unión a proteínas antiespicula y usos de estas
MX2025010056A (es) Moléculas multivalentes de unión a proteínas antiespicula y usos de estas
AR122100A1 (es) Proteínas multiespecíficas